Although no animal or human studies have been done on using MiraLAX (polyethylene glycol 3350) during pregnancy, this laxative does not enter the bloodstream. Therefore, it is unlikely that this medication would be passed to a developing fetus. However, because all of the potential risks cannot be ruled out, you should only take this drug during pregnancy if the benefits outweigh the risks.
The U.S. Food and Drug Administration (FDA) uses a category system to classify the possible risks to a fetus when a specific medicine is taken during pregnancy. Pregnancy Category C is given to medicines that have not been studied in pregnant humans but do appear to cause harm to the fetus in animal studies.
In addition, medicines that have not been adequately studied in pregnant women or animals are automatically given a pregnancy Category C rating.
MiraLAX has not been studied in pregnant animals or women. This laxative is not absorbed into the bloodstream, so it would likely not be harmful to a developing fetus. However, because of the lack of information on using MiraLAX during pregnancy, all potential risks cannot be ruled out.
In general, a pregnancy Category C medicine should be given to a pregnant woman only if the healthcare provider believes that the benefits to the woman outweigh any possible risks to the unborn child. If you require treatment for constipation during pregnancy, your healthcare provider may recommend other options, such dietary changes. If medication is needed, your healthcare provider may recommend MiraLAX if safer alternatives are not available.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click